Jazz Pharmaceuticals to Present Xywav Narcolepsy Data at 2026 AAN Annual Meeting
New poster presentation will detail self-reported outcomes in patients with narcolepsy treated with high dosages of low-sodium oxybate in the DUET study.
Tag: Jazz Pharmaceuticals
All
Latest
All
Latest
Jazz Pharmaceuticals CEO to Retire, Succession Search Underway
Bruce Cozadd, co-founder, chairperson, and CEO of Jazz, announced plans to retire as CEO upon the appointment of a successor by the end of 2025.
All
Latest
Jazz Challenges FDA on Lumryz Approval, Avadel Responds
Jazz Pharmaceuticals is challenging the FDA in district court over the FDA’s recent approval of a competing new narcolepsy drug, Lumryz.
Jazz Announces New Xywav Studies Among 13 Sleep Medicine Abstracts at SLEEP 2024
Research includes phase 4 study design of low-sodium oxybate, Xywav efficacy in narcolepsy with psychiatric and neurologic comorbidities, and assessments of idiopathic hypersomnia burden.
Read More
Digital Medicine Society Introduces Core Measures for Sleep Assessments
The core digital measures of sleep are designed to increase the availability of high-quality sleep assessments in a natural environment and improve research to advance overall population health.
Read More
Jazz to Highlight Narcolepsy and IH Research at AAN 2024
The research includes an oral presentation revealing that individuals with idiopathic hypersomnia experienced higher odds of comorbid conditions, such as cardiovascular disease.
Read More
Jazz and Avadel Both Secure Wins in Patent Lawsuit Over Narcolepsy Drug
A jury from the United States District Court for the District of Delaware delivered a mixed verdict in a patent lawsuit between Jazz Pharmaceuticals Inc and Avadel Pharmaceuticals plc concerning Avadel’s narcolepsy medication Lumryz.
Read More
Xywav Drives Jazz Pharmaceuticals’ Sleep Revenue to Over $1.9 Billion in 2023
Jazz exited the fourth quarter with approximately 12,300 active Xywav patients, up from 12,050 in the previous quarter.
Read More
How to Select the Most Suitable Pharmacotherapy for Type 1 Narcolepsy Patients
Sleep specialists share practical tips on choosing medications that treat narcolepsy symptoms, including excessive daytime sleepiness and cataplexy.
Read More
‘Rare’ Sleep Disorder More Common Than Expected
New research has found that a sleep disorder thought to be rare may be as common as some other neurologic and psychiatric conditions such as epilepsy, bipolar disorder, and schizophrenia.
Read More
Jazz Pauses Orexin Agonist Trial After Reports of ‘Visual Disturbances’
Jazz Pharmaceuticals is pausing its phase 1 clinical trial investigating JZP441, an oral orexin-2 receptor agonist with potential application for the treatment of narcolepsy and other sleep disorders, after reports of adverse effects.
Read More
Xywav Maintains Upward Trajectory in Narcolepsy and Idiopathic Hypersomnia Treatment
In the third quarter, low-sodium Xywav grew 30% year-over-year, despite additional competition, with continued adoption across both narcolepsy and idiopathic hypersomnia
Read More
Jazz Highlights Continued Need for Low-Sodium Treatment Option for Narcolepsy and IH
Jazz Pharmaceuticals announced new data highlighting the importance of low-sodium treatment options to help manage cardiovascular risk in patients with narcolepsy and idiopathic hypersomnia.
Read More
Jazz Spotlights Heart Risks Linked to Narcolepsy and Idiopathic Hypersomnia
At World Sleep 2023, Jazz Pharmaceuticals will spotlight the link between sleep disorders and cardiovascular health through 14 abstracts.
Read More
Could Daytime Sleepiness Drug Treat ADHD?
In a small clinical trial, solriamfetol—approved for treating excessive daytime sleepiness caused by narcolepsy or obstructive sleep apnea—was an effective therapy for attention-deficit/hyperactivity disorder in adults.
Read More
Jazz: Oxybate Enhances Sleep Quality in Narcolepsy Patients Regardless of Dosing Schedule
The review evaluated all high-sodium oxybates, fixed-dose, and twice-nightly administrations in both oxybate-experienced patients and those who had not undergone prior treatment.
Read More
Low-Sodium Xywav Leads Jazz Pharma’s Oxybate Revenues
During the second quarter, Jazz Pharmaceuticals registered a 39% year-over-year growth in net product sales of its low-sodium Xywav.
Read More
Xyrem Generic for Narcolepsy Launches in US
Sodium oxybate oral solution is a central nervous system depressant indicated for the treatment of cataplexy or excessive daytime sleepiness in patients aged 7 and older with narcolepsy.
Read More